Bundle Blocks 1

Lung Cancer Awareness

Lung cancer develops when healthy cells start to change and grow in an uncontrolled way. These cells usually form a mass called a tumor. There are two major types of lung cancer: non-small cell and small cell. They are usually treated in different ways. Lung cancer is the second most common cancer diagnosed in both men and women in the United States.

Our friends at SURVIVEiT have developed lung cancer resources that have been reviewed and approved as "best in class" by Team SURVIVEiT®'s medical and survivor advisory boards. Visit their lung cancer resources page to find related medical, financial, and support resources specific to lung cancer.

AI is Changing the Face of Medical Treatment

AI is Changing the Face of Medical Treatment

When you hear the term “artificial intelligence,” you might picture the evil AI overlords from The Matrix that feed on humans, or the androids in Blade Runner relegated to the dangerous task of interplanetary mining. These representations of AI are definitely entertaining, but Hollywood Sci-Fi movies have obscured the practical applications of AI in the real world.

Treating cancer involves a complexity of tests and expert analysis in order to determine the best course of action. Historically, these treatment plans have been developed based on a “one-size-fits-all” approach, without much consideration given to the genomic drivers of the individual’s particular type of cancer.

With new advancements in personalized medicine and cognitive computing, however, treatment therapies can now be tailored to a patient based on their individual genomic profile.

Two companies making improvements in efficiency and decision making in this area are Avera Health and Viviphi, Ltd.  

Viviphi and Avera Health Confirm Clinical Validation and System-Wide Implementation of the PrecisionPlan™ Cognitive Computing Platform

Viviphi and Avera Health Confirm Clinical Validation and System-Wide Implementation of the PrecisionPlan™ Cognitive Computing Platform

Viviphi Ltd (Greenwood Village, CO) and Avera Health (Sioux Falls, SD) announced today that the PrecisionPlan™ platform will be fully implemented across the multi-state cancer system. The platform was developed through a clinical collaboration in precision medicine between the two organizations. PrecisionPlan™ is a cognitive computing platform that generates comprehensive, actionable and patient-specific treatment plans in a matter of seconds. The artificial intelligence solution combines patient-specific diagnostic, surgical and demographic data from the electronic medical record (EMR) with genomic and tumor sequencing information to generate personalized treatment plans that comply with nationally respected evidence and the latest clinical guidance in precision medicine.

Viviphi Announces Appointment of Howard L. McLeod, PharmD, to the position of Senior Research Advisor in Precision Medicine and Member of Precision Medicine Advisory Board

Viviphi Announces Appointment of Howard L. McLeod, PharmD, to the position of Senior Research Advisor in Precision Medicine and Member of Precision Medicine Advisory Board

Viviphi Ltd (Greenwood Village, CO) announced the appointment of Dr. Howard McLeod, to the position of Senior Research Advisor in Precision Medicine.  McLeod will also join the Viviphi Precision Medicine Clinical Advisory Board.   He is well known to the Precision Medicine community given his leadership responsibilities for the Department of Individualized Cancer Management at the H. Lee Moffitt Cancer Center in Tampa Bay, Florida.

In his role with Viviphi, Dr. McLeod will assist in translating research and clinical advances in precision medicine in oncology.  He will help to drive the Viviphi™ technology roadmap and will function as an active ambassador of the Company and the PrecisionPlan™ cognitive computing platform at national and international research and clinical symposia.

Viviphi Appoints Pradip De, PhD, to the position of Director, Translational Oncology and Member of Precision Medicine Advisory Board

Viviphi Appoints Pradip De, PhD, to the position of Director, Translational Oncology and Member of Precision Medicine Advisory Board

Viviphi Ltd (Greenwood Village, CO) announced the appointment of Dr. Pradip De to the position of Director of Translational Oncology.   Dr. De is the Senior Scientist and Head of Translational Oncology at the Avera Cancer Institute Center for Precision Oncology. He holds the position of Assistant Professor in the Department of Internal Medicine at the University of South Dakota Sanford School of Medicine.

In his role with Viviphi, and in light of his superb comprehension of oncogenic signaling pathways, Dr. De will support the development, maintenance, testing and validation of sequence-guided oncology treatment rules. These codified clinical rules enable the translation of patient specific data into actionable knowledge for physicians to implement through the Viviphi™ cognitive computing platform known as PrecisionPlan™. Precision medicine in oncology is becoming a new standard of care in cancer medicine, and Viviphi has created a first-of-its-kind precision medicine planning platform that produces actionable and patient-specific treatment plans in real time.

Avera Innovations in the Management of Cancer Conference – A Focus on Breast

Avera Innovations in the Management of Cancer Conference – A Focus on Breast

National and international experts will convene at Avera in Sioux Falls, South Dakota to discuss the latest techniques in breast cancer treatment.

Designed to provide surgeons, radiation oncologists and medical oncologists practice innovations from national and international experts on topics of electron based intra-operative radiation therapy, genomic targeted therapy and oncoplastic surgery techniques.

The conference will focus on the role of genomics, oncoplastic surgery techniques, electron-based intraoperative radiation therapy, neoadjuvant chemotherapy, and the future of surgery and radiation oncology. Attendees will include Surgeons, Radiation Oncologists, Medical Oncologists, and representatives from pharmaceuticals.

The course directors include Julie Reiland, MD, FACS, who specializes in breast cancer treatment and technology at Avera, and Brian Leyland-Jones, MB BS PhD, Vice President of Avera Cancer Institute for Precision Oncology and Vice President of Molecular and Experimental Medicine at Avera.

Precision Medicine World Conference

Precision Medicine World Conference

Dr. Howard McLeod from the Moffitt Cancer Center and Dr. Fred Ashbury, Chief Scientific Officer at Viviphi, will host a discussion on the challenges and lessons learned to implement a precision medicine program in oncology at the Precision Medicine World Conference at Duke University on Wednesday, May 24.

Session Synopsis: Precision Medicine (PM) leaders will discuss issues and lessons learned implementing PM programs as well as opportunities for community oncology practices. Topics include: requirements for creating a precision medicine program (personnel, supports); working with sequencing labs;interpreting results; and tools needed to scale and bring genomic-guided therapies to physicians and patients. A presentation of the PrecisionPlan™ oncology workbench to facilitate patient-specific genomic-guided treatment plans at point-of-care in real-time will support the discussion.

Viviphi Ltd and Avera Health Announce a Strategic Collaboration Agreement for Precision Medicine

Viviphi Ltd and Avera Health Announce a Strategic Collaboration Agreement for Precision Medicine

DENVER — (December 15, 2016) — Viviphi Ltd and Avera Health (Sioux Falls, SD) announced today a first-of-its-kind clinical collaboration in precision medicine for oncology.  The strategic collaboration will combine Avera’s world leading position in evidence-based knowledge and practical application of genomic-based precision medicine for cancer patients with Viviphi’s patent pending Artificial Intelligence (“AI”) comprehensive clinical pathway and precision medicine planning platform.  Avera’s preeminent molecular cancer knowledge, along with nationally accepted standards of care, will be made accessible, in real time, to patients and treatment teams around the world via Viviphi’s AI-based OKaaS™ (Oncology Knowledge as a Service) platform.